产品
编 号：F177905
分子式：C21H24FN3O4
分子量：401.43
分子式：C21H24FN3O4
分子量：401.43
产品类型
规格
价格
是否有货
100mg
400
In-stock
500mg
880
In-stock
结构图
CAS No: 151096-09-2
产品详情
生物活性：
Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
体内研究：
Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic.Animal Model:144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia
Dosage:12 mg/kg
Administration:Intravenous injection; once per day, twice per day, three times per day; for 7 days
Result:Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic.
体外研究：
The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation.
Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
体内研究：
Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic.Animal Model:144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia
Dosage:12 mg/kg
Administration:Intravenous injection; once per day, twice per day, three times per day; for 7 days
Result:Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic.
体外研究：
The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备